Views: 1,464 | Downloads:
24
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Intrapartum and Neonatal Zidovudine Treatment in Reduction of Perinatal HIV -1 Transmission in Bangkok
Thaithumyanon P 
,
Thisyakom U ,
Limpongsanurak S ,
Chaithongwongwatthana S ,
Punnahitanon S ,
Ubolyam S ,
Phanuphak P ,
Ruxrungtham K ,
Virutamasen P
,
Thisyakom U ,
Limpongsanurak S ,
Chaithongwongwatthana S ,
Punnahitanon S ,
Ubolyam S ,
Phanuphak P ,
Ruxrungtham K ,
Virutamasen P Objective : To evaluate the efficacy of zidovudine (ZDV) administered during labor and
to the infants in the first 6 weeks of life in reduction of perinatal HIV -1 transmission.
Design : Open label clinical trial.
Site : King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Material and Method : One hundred asymptomatic, antiretroviral naive HIV -1 infected
pregnant women who had either late or no prenatal care were recruited from the obstetric service
of King Chulalongkorn Memorial Hospital, Bangkok, Thailand. They were given ZDV 300 mg orally
every 3 hours during the intrapartum period until delivery. ZDV syrup 2 mg/kg orally every 6 hours
were given to the infants immediately after birth for 6 weeks. Breast feeding was not allowed.
Infant's blood for HIV-1 PCR test was obtained at age 1 day, and 1, 3 and 6 months. HIV-antibody
test was determined at age 18 months. Infants with at least one positive HIV -1 PCR test perfomted
at or after 1 month of age or positive HIV -antibody test at age 18 months were classified as HIV -1
infected infants.
Results : There were 100 healthy infants delivered without complication. Fourteen infants
were excluded due to; 13 lost to follow-up and 1 drug intolerance. Of the remaining 86 infants
who were followed-up, 27 infants (31.4%) did not receive intrapartum ZDV treatment and 9 infants
were HIV-1 infected. The perinatal transmission rate was 10.5 per cent, (95% CI 3.9, 17.1).
Conclusion : The result of this study suggests that intrapartum oral ZDV treatment in
asymptomatic HIV -1 infected mothers together with ZDV treatment in the neonates for 6 weeks
can reduce the rate of perinatal HIV -1 transmission. This regimen may be an alternative treatment
for prevention of HIV -1 infection in infants born to HIV -1 seropositive mothers who have had
either late or no prenatal care.
Key ward : Perinatal Transmission, HIV, Intrapartum Treatment, Neonatal Treatment
to the infants in the first 6 weeks of life in reduction of perinatal HIV -1 transmission.
Design : Open label clinical trial.
Site : King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Material and Method : One hundred asymptomatic, antiretroviral naive HIV -1 infected
pregnant women who had either late or no prenatal care were recruited from the obstetric service
of King Chulalongkorn Memorial Hospital, Bangkok, Thailand. They were given ZDV 300 mg orally
every 3 hours during the intrapartum period until delivery. ZDV syrup 2 mg/kg orally every 6 hours
were given to the infants immediately after birth for 6 weeks. Breast feeding was not allowed.
Infant's blood for HIV-1 PCR test was obtained at age 1 day, and 1, 3 and 6 months. HIV-antibody
test was determined at age 18 months. Infants with at least one positive HIV -1 PCR test perfomted
at or after 1 month of age or positive HIV -antibody test at age 18 months were classified as HIV -1
infected infants.
Results : There were 100 healthy infants delivered without complication. Fourteen infants
were excluded due to; 13 lost to follow-up and 1 drug intolerance. Of the remaining 86 infants
who were followed-up, 27 infants (31.4%) did not receive intrapartum ZDV treatment and 9 infants
were HIV-1 infected. The perinatal transmission rate was 10.5 per cent, (95% CI 3.9, 17.1).
Conclusion : The result of this study suggests that intrapartum oral ZDV treatment in
asymptomatic HIV -1 infected mothers together with ZDV treatment in the neonates for 6 weeks
can reduce the rate of perinatal HIV -1 transmission. This regimen may be an alternative treatment
for prevention of HIV -1 infection in infants born to HIV -1 seropositive mothers who have had
either late or no prenatal care.
Key ward : Perinatal Transmission, HIV, Intrapartum Treatment, Neonatal Treatment
Download:
PDF